EGFR and lung adenocarcinoma: As available tumor samples for mutational analyses in advanced stage cancers were limited to small biopsies (378 [88.1%] of 429 specimens of stage IV lung adenocarcinomas) or cell blocks of cytologic specimens (33 [7.7%] of 429), detection of EGFR mutations by direct sequencing might be suboptimal in advanced stage disease.